AMENDMENTS TO THE CLAIMS:

The listing of claims will replace all prior versions and listings of claims in the application:

1. to 14 (Cancelled)

15. (Presently amended) A method of preventing or treating a condition in a ~~male~~ subject ~~which is caused by androgen deficiency or which can be ameliorated by androgen replacement~~ which condition is selected from the group consisting of osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, ~~periodontal disease, HIV wasting, cancer cachexia, obesity, aplastic and other anemias, and muscular dystrophies,~~ sarcopenia, and frailty comprising administering to the ~~male~~ subject in need of such prevention or treatment a prophylactically or therapeutically effective amount of a compound of formula I:



(I)

or a pharmaceutically acceptable salt thereof; wherein

"a" represents a single bond or a double bond;

R^1 is hydrogen, hydroxymethyl, or C_{1-3} alkyl, wherein alkyl is unsubstituted or substituted with one to seven fluorine atoms;

R^2 is hydrogen, fluorine, or C_{1-4} alkyl when "a" represents a double bond; or two R^2 substituents are each independently hydrogen, fluorine, or C_{1-4} alkyl when "a" represents a single bond;

R^3 is hydrogen or C_{1-3} alkyl;

R^4 is hydrogen, C_{1-4} alkyl, C_{2-4} alkenyl, or C_{2-4} alkynyl;

one of R^5 and R^6 is hydrogen or methyl and the other is selected from the group consisting of

(a) hydrogen,

(b) C_{1-8} alkyl,

(c) C_{2-8} alkenyl,

wherein alkyl and alkenyl are unsubstituted or substituted one to three groups independently selected from amino, cyano, halogen, hydroxy, oxo, carboxy, C_{1-4} alkoxy, C_{1-4} alkoxyC_{1-4} alkoxy, and C_{1-3} alkyloxycarbonyl;

(d) fluoro,
(e) cyano,
(f) hydroxy,
(g) C_{1-6} alkoxy,
(h) C_{1-6} alkylcarbonyloxy,
(i) C_{1-6} alkylthio,
(j) C_{1-6} alkylsulfonyl,
(k) C_{3-8} cycloalkyl C_{0-6} alkyl,
(l) C_{3-8} cycloheteroalkyl C_{0-6} alkyl,
(m) aryl C_{0-6} alkyl,
(n) aryl C_{2-4} alkenyl,
(o) amino,
(p) C_{1-3} acylamino,
(q) aryl C_{1-3} acylamino,
(r) C_{1-6} alkylamino,
(s) di(C_{1-6} alkyl)amino,
(t) aryl C_{0-3} alkylamino,
(u) di(aryl C_{0-3} alkyl)amino,
(v) C_{3-6} cycloalkyl C_{0-2} alkylamino,
(w) C_{1-8} alkylsulfonylamino,
(x) aryl C_{0-3} alkylsulfonylamino,
(y) C_{1-8} alkyloxycarbonylamino,
(z) aryl C_{0-3} alkyloxycarbonylamino,
(aa) aminocarbonylamino,
(bb) C_{1-8} alkylaminocarbonylamino,
(cc) aryl C_{0-3} alkylaminocarbonylamino,
(dd) C_{1-8} alkylaminocarbonyloxy, and
(ee) aryl C_{0-3} alkylaminocarbonyloxy;

or R^5 and R^6 taken together with the carbon atom to which they are attached can form a C_{3-6} spirocyclic ring system optionally containing a heteroatom selected from O, S, and NC_{0-4} alkyl;

or R^5 and R^6 taken together can be $=CR^9R^{10}$, wherein R^9 and R^{10} are each independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-3} alkyl, C_{3-6} cycloheteroalkyl C_{0-3} alkyl, and aryl C_{0-3} alkyl; or R^9 and R^{10} taken together with the carbon atom to which they are attached can form a 3- to 6-membered ring optionally containing a heteroatom selected from O, S, NH,
NC_{1-4} alkyl, and NC_{1-4} alkyloxycarbonyl;

wherein the aryl group above is selected from the group consisting of

(1) phenyl,
(2) naphthyl,
(3) benzimidazolyl,
(4) benzofuranyl,
(5) benzothiophenyl,
(6) benzoxazolyl,
(7) benzothiazolyl,
(8) benzodihydrofuranyl,
(9) 1,3-benzodioxolyl,
(10) indolyl,
(11) quinolyl,
(12) isoquinolyl,
(13) furanyl,
(14) thienyl,
(15) imidazolyl,
(16) oxazolyl,
(17) thiazolyl,
(18) isoxazolyl,
(19) isothiazolyl,
(20) pyrazolyl,
(21) pyrrolyl,
(22) pyridyl,
(23) pyrimidyl,
(24) pyrazinyl,
(25) thiadiazolyl,
(26) oxadiazolyl,
(27) triazolyl, and
(28) tetrazolyl;

wherein the aryl group as defined in items (1) to (28) is unsubstituted or substituted with one to three groups independently selected from halogen, aryl, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{3-8} cycloheteroalkyl, aryl C_{1-6}alkyl, amino C_{0-6}alkyl, C_{1-6} alkylamino C_{0-6}alkyl, (C_{1-6} alkyl)$_2$amino C_{0-6}alkyl, aryl C_{0-6} alkylamino C_{0-6}alkyl, (aryl C_{0-6} alkyl)$_2$amino C_{0-6}alkyl, C_{1-6} alkylthio, aryl C_{0-6}alkylthio, C_{1-6} alkylsulfinyl, aryl C_{0-6}alkylsulfinyl, C_{1-6} alkylsulfonyl, aryl C_{0-6}alkylsulfonyl, C_{1-6} alkoxy C_{0-6}alkyl, aryl C_{0-6} alkoxy C_{0-6}alkyl, hydroxycarbonyl C_{0-6}alkyl, C_{1-6} alkoxycarbonyl C_{0-6}alkyl, aryl C_{0-6} alkoxycarbonyl C_{0-6}alkyl, hydroxycarbonyl C_{1-6} alkyloxy, hydroxy C_{0-6}alkyl, cyano, nitro, perfluoroC_{1-4}alkyl, perfluoroC_{1-4}alkoxy, oxo, C_{1-6} alkylcarbonyloxy, aryl C_{0-6}alkylcarbonyloxy, C_{1-6} alkylcarbonylamino, aryl C_{0-6} alkylcarbonylamino, C_{1-6} alkylsulfonylamino, aryl C_{0-6}alkylsulfonylamino, C_{1-6} alkoxycarbonylamino, aryl C_{0-6} alkoxycarbonylamino, C_{1-6}alkylamino-carbonylamino, aryl C_{0-6}alkylaminocarbonylamino, (C_{1-6}alkyl)$_2$ aminocarbonylamino, (aryl C_{0-6}alkyl)$_2$ aminocarbonylamino, (C_{1-6}alkyl)$_2$ aminocarbonyloxy, and (aryl C_{0-6}alkyl)$_2$ aminocarbonyloxy.

16. (Original) The method of Claim 15 wherein said condition is osteoporosis.

17. (Original) The method of Claim 15 wherein the compound is of structural formula III:



(III)

or a pharmaceutically acceptable salt thereof; wherein
"a" represents a single bond or a double bond;
R^1 is hydrogen, hydroxymethyl, or C_{1-3} alkyl, wherein alkyl is unsubstituted or substituted with one to seven fluorine atoms;
R^2 is hydrogen, fluorine, or C_{1-4} alkyl when "a" represents a double bond; or two R^2 substituents are each independently hydrogen, fluorine, or C_{1-4} alkyl when "a" represents a single bond;

one of R^5 and R^6 is hydrogen or methyl and the other is selected from the group consisting of

(a) hydrogen,

(b) C_{1-8} alkyl,

(c) C_{2-8} alkenyl,

wherein alkyl and alkenyl are unsubstituted or substituted one to three groups independently selected from amino, cyano, halogen, hydroxy, oxo, carboxy, C_{1-4} alkoxy, C_{1-4} alkoxyC_{1-4} alkoxy, and C_{1-3} alkyloxycarbonyl;

(d) fluoro,

(e) cyano,

(f) hydroxy,

(g) C_{1-6} alkoxy,

(h) C_{1-6} alkylcarbonyloxy,

(i) C_{1-6} alkylthio,

(j) C_{1-6} alkylsulfonyl,

(k) C_{3-8} cycloalkyl C_{0-6} alkyl,

(l) C_{3-8} cycloheteroalkyl C_{0-6} alkyl,

(m) aryl C_{0-6} alkyl,

(n) aryl C_{2-4} alkenyl,

(o) amino,

(p) C_{1-3} acylamino,

(q) aryl C_{1-3} acylamino,

(r) C_{1-6} alkylamino,

(s) di(C_{1-6} alkyl)amino,

(t) aryl C_{0-3} alkylamino,

(u) di(aryl C_{0-3} alkyl)amino,

(v) C_{3-6} cycloalkyl C_{0-2} alkylamino,

(w) C_{1-8} alkylsulfonylamino,

(x) aryl C_{0-3} alkylsulfonylamino,

(y) C_{1-8} alkyloxycarbonylamino,

(z) aryl C_{0-3} alkyloxycarbonylamino,

(aa) aminocarbonylamino,

(bb) C_{1-8} alkylaminocarbonylamino,

(cc) aryl C_{0-3} alkylaminocarbonylamino,

(dd) C_{1-8} alkylaminocarbonyloxy, and

(ee) aryl C_{0-3} alkylaminocarbonyloxy;

or R^5 and R^6 taken together with the carbon atom to which they are attached can form a C_{3-6} spirocyclic ring system optionally containing a heteroatom selected from O, S, and NC_{0-4} alkyl;

or R^5 and R^6 taken together can be $=CR^9R^{10}$, wherein R^9 and R^{10} are each independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-3} alkyl, C_{3-6} cycloheteroalkyl C_{0-3} alkyl, and aryl C_{0-3} alkyl; or R^9 and R^{10} taken together with the carbon atom to which they are attached can form a 3- to 6-membered ring optionally containing a heteroatom selected from O, S, NH, NC_{1-4} alkyl, and NC_{1-4} alkyloxycarbonyl;

wherein the aryl group above is selected from the group consisting of

(1) phenyl,
(2) naphthyl,
(3) benzimidazolyl,
(4) benzofuranyl,
(5) benzothiophenyl,
(6) benzoxazolyl,
(7) benzothiazolyl,
(10) benzodihydrofuranyl,
(11) 1,3-benzodioxolyl,
(10) indolyl,
(11) quinolyl,
(12) isoquinolyl,
(13) furanyl,
(14) thienyl,
(15) imidazolyl,
(16) oxazolyl,
(17) thiazolyl,
(18) isoxazolyl,
(19) isothiazolyl,
(20) pyrazolyl,
(21) pyrrolyl,
(22) pyridyl,
(23) pyrimidyl,
(24) pyrazinyl,
(25) thiadiazolyl,

(26) oxadiazolyl,

(27) triazolyl, and

(28) tetrazolyl;

wherein the aryl group as defined in items (1) to (28) is unsubstituted or substituted with one to three groups independently selected from halogen, aryl, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{3-8} cycloheteroalkyl, aryl C_{1-6}alkyl, amino C_{0-6}alkyl, C_{1-6} alkylamino C_{0-6}alkyl, (C_{1-6} alkyl)$_2$amino C_{0-6}alkyl, aryl C_{0-6} alkylamino C_{0-6}alkyl, (aryl C_{0-6} alkyl)$_2$amino C_{0-6}alkyl, C_{1-6} alkylthio, aryl C_{0-6}alkylthio, C_{1-6} alkylsulfinyl, aryl C_{0-6}alkylsulfinyl, C_{1-6} alkylsulfonyl, aryl C_{0-6}alkylsulfonyl, C_{1-6} alkoxy C_{0-6}alkyl, aryl C_{0-6} alkoxy C_{0-6}alkyl, hydroxycarbonyl C_{0-6}alkyl, C_{1-6} alkoxycarbonyl C_{0-6}alkyl, aryl C_{0-6} alkoxycarbonyl C_{0-6}alkyl, hydroxycarbonyl C_{1-6} alkyloxy, hydroxy C_{0-6}alkyl, cyano, nitro, perfluoroC_{1-4}alkyl, perfluoroC_{1-4}alkoxy, oxo, C_{1-6} alkylcarbonyloxy, aryl C_{0-6}alkylcarbonyloxy, C_{1-6} alkylcarbonylamino, aryl C_{0-6} alkylcarbonylamino, C_{1-6} alkylsulfonylamino, aryl C_{0-6}alkylsulfonylamino, C_{1-6} alkoxycarbonylamino, aryl C_{0-6} alkoxycarbonylamino, C_{1-6}alkylamino-carbonylamino, aryl C_{0-6}alkylaminocarbonylamino, (C_{1-6}alkyl)$_2$ aminocarbonylamino, (aryl C_{0-6}alkyl)$_2$ aminocarbonylamino, (C_{1-6}alkyl)$_2$ aminocarbonyloxy, and (aryl C_{0-6}alkyl)$_2$ aminocarbonyloxy.

18. (Original) The method of Claim 15 wherein the compound is selected from the group consisting of:

17β-hydroxy-7β-methyl-4-aza-5α-androst-1-en-3-one;

17α-hydroxy-7β-methyl-4-aza-5α-androst-1-en-3-one;

17β-hydroxy-4,16α-dimethyl-4-aza-5α-androst-1-en-3-one;

17β-hydroxy-4,16β-dimethyl-4-aza-5α-androst-1-en-3-one;

16α-fluoro-17β-hydroxy-4-methyl-4-aza-5α-androst-1-en-3-one;

16β-fluoro-17α-hydroxy-4-methyl-4-aza-5α-androst-1-en-3-one;

16α-fluoro-17β-hydroxy-4,17α-dimethyl-4-aza-5α-androst-1-en-3-one;

16β-fluoro-17β-hydroxy-4-methyl-4-aza-5α-androst-1-en-3-one;

2α-fluoro-17β-hydroxy-4-methyl-4-aza-5α-androstan-3-one;

2β-fluoro-17β-hydroxy-4-methyl-4-aza-5α-androstan-3-one;

2,2-difluoro-17β-hydroxy-4-methyl-4-aza-5α-androstan-3-one;

17β-hydroxy-2α,4-dimethyl-4-aza-5α-androstan-3-one;

17β-hydroxy-16α-(methoxymethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;

17β-hydroxy-16α-(ethoxymethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;

17β-hydroxy-16α-(2-methoxyethyloxymethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;

17β-hydroxy-16α-(ethyloxycarbonylmethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(carboxymethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(2-hydroxyethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-allyl-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-4,16α,17α-trimethyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-4-methyl-4-aza-5α-androstan-3-one;
17β-hydroxy-4,17α-dimethyl-4-aza-5α-androstan-3-one;
17β-hydroxy-17α-ethyl-4-methyl-4-aza-5α-androstan-3-one;
17β-hydroxy-4,17α-dimethyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(2-trifluoromethylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(3-trifluoromethylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(4-trifluoromethylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(2-fluorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(3-fluorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(4-fluorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(3-chlorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(4-chlorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(4-trifluoromethoxybenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(3-methoxybenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-benzyl-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(2-methylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(2-naphthyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16β-(2-methylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16β-(3-methylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16β-(4-chlorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-chlorobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-fluorobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-trifluoromethylbenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-trifluoromethylbenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-methoxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3,4-methylenedioxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(5-methoxy-3,4-methylenedioxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3,5-difluorobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3,5-dichlorobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;

17β-hydroxy-16-(3,4-dimethoxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(pyridin-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(pyridin-4-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(cyclopropylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(furan-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(1-methyl-imidazol-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-cyclohexylidene-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-ethylidene-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-isopropylidene-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-isobutylidene-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(piperidin-4-ylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(N-t-butyloxycarbonylpiperidin-4-ylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(1,3-thiazol-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(benzofuran-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(5-hydroxymethyl-furan-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(1-methyl-pyrrol-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(pyrrol-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-ethoxy-pyrimidin-5-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(pyrimidin-5-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-methyl-pyrimidin-5-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-trifluoromethoxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(4-trifluoromethoxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(4-dimethylaminobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(9-methoxy-quinolin-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(quinoxalin-6-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(quinoxalin-7-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-hydroxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-hydroxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(4-hydroxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;

17β-hydroxy-16-(pyridin-3-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(N-methylpiperidin-4-ylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-chloro-4-dimethylaminobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-amino-pyridin-3-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-carboxymethyl-benzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-carboxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-nitrobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(4-nitrobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one; and
17β-hydroxy-16-(benzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
or a pharmaceutically acceptable salt thereof.

19. (Presently amended) A method of preventing or treating a condition in a female subject which is caused by androgen deficiency or which can be ameliorated by androgen replacement which condition is selected from the group consisting of postmenopausal osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, ~~periodontal disease, HIV-wasting, cancer cachexia, obesity, aplastic and other anemias, muscular dystrophies, premature ovarian failure, and autoimmune disease,~~ sarcopenia and frailty comprising administering to the female subject in need of such prevention or treatment a prophylactically or therapeutically effective amount of a compound of formula I:



(I)

or a pharmaceutically acceptable salt thereof; wherein
"a" represents a single bond or a double bond;
R^1 is hydrogen, hydroxymethyl, or C_{1-3} alkyl, wherein alkyl is unsubstituted or substituted with one to seven fluorine atoms;
R^2 is hydrogen, fluorine, or C_{1-4} alkyl when "a" represents a double bond; or two R^2 substituents are each independently hydrogen, fluorine, or C_{1-4} alkyl when "a" represents a single bond;

R^3 is hydrogen or C_{1-3} alkyl;

R^4 is hydrogen, C_{1-4} alkyl, C_{2-4} alkenyl, or C_{2-4} alkynyl;

one of R^5 and R^6 is hydrogen or methyl and the other is selected from the group consisting of

(a) hydrogen,

(b) C_{1-8} alkyl,

(c) C_{2-8} alkenyl,

wherein alkyl and alkenyl are unsubstituted or substituted one to three groups independently selected from amino, cyano, halogen, hydroxy, oxo, carboxy, C_{1-4} alkoxy, C_{1-4} alkoxyC_{1-4} alkoxy, and C_{1-3} alkyloxycarbonyl;

(d) fluoro,

(e) cyano,

(f) hydroxy,

(g) C_{1-6} alkoxy,

(h) C_{1-6} alkylcarbonyloxy,

(i) C_{1-6} alkylthio,

(j) C_{1-6} alkylsulfonyl,

(k) C_{3-8} cycloalkyl C_{0-6} alkyl,

(l) C_{3-8} cycloheteroalkyl C_{0-6} alkyl,

(m) aryl C_{0-6} alkyl,

(n) aryl C_{2-4} alkenyl,

(o) amino,

(p) C_{1-3} acylamino,

(q) aryl C_{1-3} acylamino,

(r) C_{1-6} alkylamino,

(s) di(C_{1-6} alkyl)amino,

(t) aryl C_{0-3} alkylamino,

(u) di(aryl C_{0-3} alkyl)amino,

(v) C_{3-6} cycloalkyl C_{0-2} alkylamino,

(w) C_{1-8} alkylsulfonylamino,

(x) aryl C_{0-3} alkylsulfonylamino,

(y) C_{1-8} alkyloxycarbonylamino,

(z) aryl C_{0-3} alkyloxycarbonylamino,

(aa) aminocarbonylamino,

(bb) C_{1-8} alkylaminocarbonylamino,

(cc) aryl C_{0-3} alkylaminocarbonylamino,

(dd) C_{1-8} alkylaminocarbonyloxy, and

(ee) aryl C_{0-3} alkylaminocarbonyloxy;

or R^5 and R^6 taken together with the carbon atom to which they are attached can form a C_{3-6} spirocyclic ring system optionally containing a heteroatom selected from O, S, and NC_{0-4} alkyl;

or R^5 and R^6 taken together can be $=CR^9R^{10}$, wherein R^9 and R^{10} are each independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-3} alkyl, C_{3-6} cycloheteroalkyl C_{0-3} alkyl, and aryl C_{0-3} alkyl; or R^9 and R^{10} taken together with the carbon atom to which they are attached can form a 3- to 6-membered ring optionally containing a heteroatom selected from O, S, NH, NC_{1-4} alkyl, and NC_{1-4} alkyloxycarbonyl;

wherein the aryl group above is selected from the group consisting of

(1) phenyl,
(2) naphthyl,
(3) benzimidazolyl,
(4) benzofuranyl,
(5) benzothiophenyl,
(6) benzoxazolyl,
(7) benzothiazolyl,
(12) benzodihydrofuranyl,
(13) 1,3-benzodioxolyl,
(10) indolyl,
(11) quinolyl,
(12) isoquinolyl,
(13) furanyl,
(14) thienyl,
(15) imidazolyl,
(16) oxazolyl,
(17) thiazolyl,
(18) isoxazolyl,
(19) isothiazolyl,
(20) pyrazolyl,
(21) pyrrolyl,
(22) pyridyl,
(23) pyrimidyl,

(24) pyrazinyl,
(25) thiadiazolyl,
(26) oxadiazolyl,
(27) triazolyl, and
(28) tetrazolyl;

wherein the aryl group as defined in items (1) to (28) is unsubstituted or substituted with one to three groups independently selected from halogen, aryl, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{3-8} cycloheteroalkyl, aryl C_{1-6}alkyl, amino C_{0-6}alkyl, C_{1-6} alkylamino C_{0-6}alkyl, (C_{1-6} alkyl)$_2$amino C_{0-6}alkyl, aryl C_{0-6} alkylamino C_{0-6}alkyl, (aryl C_{0-6} alkyl)$_2$amino C_{0-6}alkyl, C_{1-6} alkylthio, aryl C_{0-6}alkylthio, C_{1-6} alkylsulfinyl, aryl C_{0-6}alkylsulfinyl, C_{1-6} alkylsulfonyl, aryl C_{0-6}alkylsulfonyl, C_{1-6} alkoxy C_{0-6}alkyl, aryl C_{0-6} alkoxy C_{0-6}alkyl, hydroxycarbonyl C_{0-6}alkyl, C_{1-6} alkoxycarbonyl C_{0-6}alkyl, aryl C_{0-6} alkoxycarbonyl C_{0-6}alkyl, hydroxycarbonyl C_{1-6} alkyloxy, hydroxy C_{0-6}alkyl, cyano, nitro, perfluoroC_{1-4}alkyl, perfluoroC_{1-4}alkoxy, oxo, C_{1-6} alkylcarbonyloxy, aryl C_{0-6}alkylcarbonyloxy, C_{1-6} alkylcarbonylamino, aryl C_{0-6} alkylcarbonylamino, C_{1-6} alkylsulfonylamino, aryl C_{0-6}alkylsulfonylamino, C_{1-6} alkoxycarbonylamino, aryl C_{0-6} alkoxycarbonylamino, C_{1-6}alkylamino-carbonylamino, aryl C_{0-6}alkylaminocarbonylamino, (C_{1-6}alkyl)$_2$ aminocarbonylamino, (aryl C_{0-6}alkyl)$_2$ aminocarbonylamino, (C_{1-6}alkyl)$_2$ aminocarbonyloxy, and (aryl C_{0-6}alkyl)$_2$ aminocarbonyloxy.

20. (Original) The method of Claim 19 wherein said condition is osteoporosis.

21. (Original) The method of Claim 19 wherein the compound is of structural formula III:



(III)

or a pharmaceutically acceptable salt thereof; wherein
"a" represents a single bond or a double bond;

R^1 is hydrogen, hydroxymethyl, or C_{1-3} alkyl, wherein alkyl is unsubstituted or substituted with one to seven fluorine atoms;
R^2 is hydrogen, fluorine, or C_{1-4} alkyl when "a" represents a double bond; or two R^2 substituents are each independently hydrogen, fluorine, or C_{1-4} alkyl when "a" represents a single bond;
one of R^5 and R^6 is hydrogen or methyl and the other is selected from the group consisting of

(a) hydrogen,
(b) C_{1-8} alkyl,
(c) C_{2-8} alkenyl,

wherein alkyl and alkenyl are unsubstituted or substituted one to three groups independently selected from amino, cyano, halogen, hydroxy, oxo, carboxy,
C_{1-4} alkoxy, C_{1-4} alkoxyC_{1-4} alkoxy, and C_{1-3} alkyloxycarbonyl;

(d) fluoro,
(e) cyano,
(f) hydroxy,
(g) C_{1-6} alkoxy,
(h) C_{1-6} alkylcarbonyloxy,
(i) C_{1-6} alkylthio,
(j) C_{1-6} alkylsulfonyl,
(k) C_{3-8} cycloalkyl C_{0-6} alkyl,
(l) C_{3-8} cycloheteroalkyl C_{0-6} alkyl,
(m) aryl C_{0-6} alkyl,
(n) aryl C_{2-4} alkenyl,
(o) amino,
(p) C_{1-3} acylamino,
(q) aryl C_{1-3} acylamino,
(r) C_{1-6} alkylamino,
(s) di(C_{1-6} alkyl)amino,
(t) aryl C_{0-3} alkylamino,
(u) di(aryl C_{0-3} alkyl)amino,
(v) C_{3-6} cycloalkyl C_{0-2} alkylamino,
(w) C_{1-8} alkylsulfonylamino,
(x) aryl C_{0-3} alkylsulfonylamino,
(y) C_{1-8} alkyloxycarbonylamino,
(z) aryl C_{0-3} alkyloxycarbonylamino,

(aa) aminocarbonylamino,
(bb) C_{1-8} alkylaminocarbonylamino,
(cc) aryl C_{0-3} alkylaminocarbonylamino,
(dd) C_{1-8} alkylaminocarbonyloxy, and
(ee) aryl C_{0-3} alkylaminocarbonyloxy;

or R^5 and R^6 taken together with the carbon atom to which they are attached can form a C_{3-6} spirocyclic ring system optionally containing a heteroatom selected from O, S, and NC_{0-4} alkyl;

or R^5 and R^6 taken together can be $=CR^9R^{10}$, wherein R^9 and R^{10} are each independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-3} alkyl, C_{3-6} cycloheteroalkyl C_{0-3} alkyl, and aryl C_{0-3} alkyl; or R^9 and R^{10} taken together with the carbon atom to which they are attached can form a 3- to 6-membered ring optionally containing a heteroatom selected from O, S, NH, NC_{1-4} alkyl, and NC_{1-4} alkyloxycarbonyl;

wherein the aryl group above is selected from the group consisting of

(1) phenyl,
(2) naphthyl,
(3) benzimidazolyl,
(4) benzofuranyl,
(5) benzothiophenyl,
(6) benzoxazolyl,
(7) benzothiazolyl,
(14) benzodihydrofuranyl,
(15) 1,3-benzodioxolyl,
(10) indolyl,
(11) quinolyl,
(12) isoquinolyl,
(13) furanyl,
(14) thienyl,
(15) imidazolyl,
(16) oxazolyl,
(17) thiazolyl,
(18) isoxazolyl,
(19) isothiazolyl,
(20) pyrazolyl,

(21) pyrrolyl,
(22) pyridyl,
(23) pyrimidyl,
(24) pyrazinyl,
(25) thiadiazolyl,
(26) oxadiazolyl,
(27) triazolyl, and
(28) tetrazolyl;

wherein the aryl group as defined in items (1) to (28) is unsubstituted or substituted with one to three groups independently selected from halogen, aryl, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{3-8} cycloheteroalkyl, aryl C_{1-6}alkyl, amino C_{0-6}alkyl, C_{1-6} alkylamino C_{0-6}alkyl, (C_{1-6} alkyl)$_2$amino C_{0-6}alkyl, aryl C_{0-6} alkylamino C_{0-6}alkyl, (aryl C_{0-6} alkyl)$_2$amino C_{0-6}alkyl, C_{1-6} alkylthio, aryl C_{0-6}alkylthio, C_{1-6} alkylsulfinyl, aryl C_{0-6}alkylsulfinyl, C_{1-6} alkylsulfonyl, aryl C_{0-6}alkylsulfonyl, C_{1-6} alkoxy C_{0-6}alkyl, aryl C_{0-6} alkoxy C_{0-6}alkyl, hydroxycarbonyl C_{0-6}alkyl, C_{1-6} alkoxycarbonyl C_{0-6}alkyl, aryl C_{0-6} alkoxycarbonyl C_{0-6}alkyl, hydroxycarbonyl C_{1-6} alkyloxy, hydroxy C_{0-6}alkyl, cyano, nitro, perfluoroC_{1-4}alkyl, perfluoroC_{1-4}alkoxy, oxo, C_{1-6} alkylcarbonyloxy, aryl C_{0-6}alkylcarbonyloxy, C_{1-6} alkylcarbonylamino, aryl C_{0-6} alkylcarbonylamino, C_{1-6} alkylsulfonylamino, aryl C_{0-6}alkylsulfonylamino, C_{1-6} alkoxycarbonylamino, aryl C_{0-6} alkoxycarbonylamino, C_{1-6}alkylamino-carbonylamino, aryl C_{0-6}alkylaminocarbonylamino, (C_{1-6}alkyl)$_2$ aminocarbonylamino, (aryl C_{0-6}alkyl)$_2$ aminocarbonylamino, (C_{1-6}alkyl)$_2$ aminocarbonyloxy, and (aryl C_{0-6}alkyl)$_2$ aminocarbonyloxy.

22. (Original) The method of Claim 19 wherein the compound is selected from the group consisting of:
17β-hydroxy-7β-methyl-4-aza-5α-androst-1-en-3-one;
17α-hydroxy-7β-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-4,16α-dimethyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-4,16β-dimethyl-4-aza-5α-androst-1-en-3-one;
16α-fluoro-17β-hydroxy-4-methyl-4-aza-5α-androst-1-en-3-one;
16β-fluoro-17α-hydroxy-4-methyl-4-aza-5α-androst-1-en-3-one;
16α-fluoro-17β-hydroxy-4,17α-dimethyl-4-aza-5α-androst-1-en-3-one;
16β-fluoro-17β-hydroxy-4-methyl-4-aza-5α-androst-1-en-3-one;
2α-fluoro-17β-hydroxy-4-methyl-4-aza-5α-androstan-3-one;
2β-fluoro-17β-hydroxy-4-methyl-4-aza-5α-androstan-3-one;

2,2-difluoro-17β-hydroxy-4-methyl-4-aza-5α-androstan-3-one;
17β-hydroxy-2α,4-dimethyl-4-aza-5α-androstan-3-one;
17β-hydroxy-16α-(methoxymethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(ethoxymethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(2-methoxyethyloxymethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(ethyloxycarbonylmethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(carboxymethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(2-hydroxyethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-allyl-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-4,16α,17α-trimethyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-4-methyl-4-aza-5α-androstan-3-one;
17β-hydroxy-4,17α-dimethyl-4-aza-5α-androstan-3-one;
17β-hydroxy-17α-ethyl-4-methyl-4-aza-5α-androstan-3-one;
17β-hydroxy-4,17α-dimethyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(2-trifluoromethylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(3-trifluoromethylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(4-trifluoromethylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(2-fluorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(3-fluorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(4-fluorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(3-chlorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(4-chlorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(4-trifluoromethoxybenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(3-methoxybenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-benzyl-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(2-methylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(2-naphthyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16β-(2-methylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16β-(3-methylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16β-(4-chlorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-chlorobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-fluorobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-trifluoromethylbenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-trifluoromethylbenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-methoxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;

17β-hydroxy-16-(3,4-methylenedioxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(5-methoxy-3,4-methylenedioxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3,5-difluorobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3,5-dichlorobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3,4-dimethoxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(pyridin-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(pyridin-4-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(cyclopropylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(furan-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(1-methyl-imidazol-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-cyclohexylidene-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-ethylidene-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-isopropylidene-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-isobutylidene-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(piperidin-4-ylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(N-t-butyloxycarbonylpiperidin-4-ylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(1,3-thiazol-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(benzofuran-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(5-hydroxymethyl-furan-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(1-methyl-pyrrol-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(pyrrol-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-ethoxy-pyrimidin-5-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(pyrimidin-5-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-methyl-pyrimidin-5-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-trifluoromethoxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(4-trifluoromethoxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(4-dimethylaminobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(9-methoxy-quinolin-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;

17β-hydroxy-16-(quinoxalin-6-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(quinoxalin-7-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-hydroxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-hydroxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(4-hydroxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(pyridin-3-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(N-methylpiperidin-4-ylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-chloro-4-dimethylaminobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-amino-pyridin-3-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-carboxymethyl-benzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-carboxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-nitrobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(4-nitrobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one; and
17β-hydroxy-16-(benzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
or a pharmaceutically acceptable salt thereof.

23. (Original) The method of Claim 20 which further comprises the administration of a bone-strengthening agent selected from the group consisting of:

(a) an estrogen or an estrogen derivative, alone or in combination with a progestin or progestin derivative,
(b) a bisphosphonate,
(c) an antiestrogen or a selective estrogen receptor modulator,
(d) an αvβ3 integrin receptor antagonist,
(e) a cathepsin K inhibitor,
(f) an HMG-CoA reductase inhibitor,
(g) an osteoclast vacuolar ATPase inhibitor,
(h) an antagonist of VEGF binding to osteoclast receptors,
(i) an activator of peroxisome proliferator-activated receptor γ,
(j) calcitonin,
(k) a calcium receptor antagonist,
(l) parathyroid hormone or analog thereof,
(m) a growth hormone secretagogue,
(n) human growth hormone,
(o) insulin-like growth factor,

(p) a P-38 protein kinase inhibitor,
(q) bone morphogenetic protein,
(r) an inhibitor of BMP antagonism,
(s) a prostaglandin derivative,
(t) vitamin D or vitamin D derivative,
(u) vitamin K or vitamin K derivative,
(v) ipriflavone,
(w) fluoride salts,
(x) dietary calcium supplement, and
(y) osteoprotegerin.

24. (Original) The method of Claim 23 wherein:

(a) the estrogen or estrogen derivative, alone or in combination with a progestin or progestin derivative, is selected from conjugated estrogen, equine estrogen, 17β-estradiol, estrone, 17β-ethynyl estradiol, alone or in combination with an agent selected from norethindrone and medroxyprogesterone acetate;

(b) the bisphosphonate is selected from:
(1) (4-amino-1-hydroxybutylidene)-bisphosphonate;
(2) [(cycloheptylamino)-methylene]-bisphosphonate;
(3) (dichloromethylene)-bisphosphonate;
(4) [1-hydroxy-3-(1-pyrrolidinyl)-propylidene]-bisphosphonate;
(5) (1-hydroxyethylidene)-bisphosphonate;
(6) [1-hydroxy-3-(methylpentylamino)propylidene]-bisphosphonate;
(7) (6-amino-1-hydroxyhexylidene)-bisphosphonate;
(8) [3-(dimethylamino)-1-hydroxypropylidene]-bisphosphonate;
(9) (3-amino-1-hydroxypropylidene)-bisphosphonate;
(10) [2-(2-pyridinyl)ethylidene]-bisphosphonate;
(11) [1-hydroxy-2-(3-pyridinyl)-ethylidene]-bisphosphonate;
(12) {[(4-chlorophenyl)thio]methylene}-bisphosphonate;
(13) [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]-bisphosphonate; and
(14) [1-hydroxy-2-imidazopyridin-(1,2-a)-3-ylethylidene]-bisphosphonate;

(c) the antiestrogen or selective estrogen receptor modulator is selected from the group consisting of raloxifene, clomiphene, zuclomiphene, enclomiphene, nafoxidene, CI-680, CI-628, CN-55,945-27, Mer-25, U-11,555A, U-100A, tamoxifen, lasofoxifene,

toremifene, azorxifene, EM-800, EM-652, TSE 424, droloxifene, idoxifene, and levormeloxifene;

(d) the HMG-CoA reductase inhibitor is selected from lovastatin, simvastatin, dihydroxy-open acid simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, rosuvastatin, pitavastatin, and nisvastatin;

(e) calcitonin is salmon calcitonin administered as a nasal spray;

(f) bone morphogenetic protein is selected from BMP 2, BMP 3, BMP 5, BMP 6, BMP 7, TGF beta, and GDF5;

(g) insulin-like growth factor is selected from IGF I and IGF II alone or in combination with IGF binding protein 3;

(h) the prostaglandin derivative is selected from agonists of prostaglandin receptors EP1, EP2, EP4, FP, and IP;

(i) the fibroblast growth factor is selected from aFGF and bFGF;

(j) parathyroid hormone (PTH) or PTH analog is selected from PTH subcutaneous injection, human PTH (1-84), human PTH (1-34), and other partial sequences, native or with substitutions;

(k) vitamin D or vitamin D derivative is selected from natural vitamin D, 25-OH-vitamin D3, 1α,25(OH)$_2$ vitamin D3, 1α-OH-vitamin D3, 1α-OH-vitamin D2, dihydrotachysterol, 26,27-F6-1α,25(OH)$_2$ vitamin D3, 19-nor-1α,25(OH)$_2$ vitamin D3, 22-oxacalcitriol, calcipotriol, 1α,25(OH)$_2$-16-ene-23-yne-vitamin D3 (Ro 23-7553), EB1089, 20-epi-1α,25(OH)$_2$ vitamin D3, KH1060, ED71, 1α,24(S)-(OH)$_2$ vitamin D3, and 1α,24(R)-(OH)$_2$ vitamin D3;

(l) the dietary calcium supplement is selected from calcium carbonate, calcium citrate, and natural calcium salts; and

(m) the fluoride salts are selected from sodium fluoride and monosodium fluorophosphate (MFP);

and pharmaceutically acceptable salts thereof.

25. (Original) The method of Claim 16 which further comprises the administration of alendronate monosodium trihydrate.

26. (Original) The method of Claim 20 which further comprises the administration of a bone-strengthening agent selected from the group consisting of:

(a) an estrogen or an estrogen derivative, alone or in combination with a progestin or progestin derivative,

(b) a bisphosphonate,
(c) an antiestrogen or a selective estrogen receptor modulator,
(d) an αvβ3 integrin receptor antagonist,
(e) a cathepsin K inhibitor,
(f) an HMG-CoA reductase inhibitor,
(g) an osteoclast vacuolar ATPase inhibitor,
(h) an antagonist of VEGF binding to osteoclast receptors,
(i) an activator of peroxisome proliferator-activated receptor γ,
(j) calcitonin,
(k) a calcium receptor antagonist,
(l) parathyroid hormone or analog thereof,
(m) a growth hormone secretagogue,
(n) human growth hormone,
(o) insulin-like growth factor,
(p) a P-38 protein kinase inhibitor,
(q) bone morphogenetic protein,
(r) an inhibitor of BMP antagonism,
(s) a prostaglandin derivative,
(t) vitamin D or vitamin D derivative,
(u) vitamin K or vitamin K derivative,
(v) ipriflavone,
(w) fluoride salts,
(x) dietary calcium supplement, and
(y) osteoprotegerin.

27. (Original) The method of Claim 26 wherein:

(a) the estrogen or estrogen derivative, alone or in combination with a progestin or progestin derivative, is selected from conjugated estrogen, equine estrogen, 17β-estradiol, estrone, 17β-ethynyl estradiol, alone or in combination with an agent selected from norethindrone and medroxyprogesterone acetate;

(b) the bisphosphonate is selected from:
(1) (4-amino-1-hydroxybutylidene)-bisphosphonate;
(2) [(cycloheptylamino)-methylene]-bisphosphonate;
(3) (dichloromethylene)-bisphosphonate;
(4) [1-hydroxy-3-(1-pyrrolidinyl)-propylidene]-bisphosphonate;

(5) (1-hydroxyethylidene)-bisphosphonate;
(6) [1-hydroxy-3-(methylpentylamino)propylidene]-bisphosphonate;
(7) (6-amino-1-hydroxyhexylidene)-bisphosphonate;
(8) [3-(dimethylamino)-1-hydroxypropylidene]-bisphosphonate;
(9) (3-amino-1-hydroxypropylidene)-bisphosphonate;
(10) [2-(2-pyridinyl)ethylidene]-bisphosphonate;
(11) [1-hydroxy-2-(3-pyridinyl)-ethylidene]-bisphosphonate;
(12) {[(4-chlorophenyl)thio]methylene}-bisphosphonate;
(13) [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]-bisphosphonate; and
(14) [1-hydroxy-2-imidazopyridin-(1,2-a)-3-ylethylidene]-bisphosphonate;

(c) the antiestrogen or selective estrogen receptor modulator is selected from the group consisting of raloxifene, clomiphene, zuclomiphene, enclomiphene, nafoxidene, CI-680, CI-628, CN-55,945-27, Mer-25, U-11,555A, U-100A, tamoxifen, lasofoxifene, toremifene, azorxifene, EM-800, EM-652, TSE 424, droloxifene, idoxifene, and levormeloxifene;

(d) the HMG-CoA reductase inhibitor is selected from lovastatin, simvastatin, dihydroxy-open acid simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, rosuvastatin, pitavastatin, and nisvastatin;

(e) calcitonin is salmon calcitonin administered as a nasal spray;

(f) bone morphogenetic protein is selected from BMP 2, BMP 3, BMP 5, BMP 6, BMP 7, TGF beta, and GDF5;

(g) insulin-like growth factor is selected from IGF I and IGF II alone or in combination with IGF binding protein 3;

(h) the prostaglandin derivative is selected from agonists of prostaglandin receptors EP1, EP2, EP4, FP, and IP;

(i) the fibroblast growth factor is selected from aFGF and bFGF;

(j) parathyroid hormone (PTH) or PTH analog is selected from PTH subcutaneous injection, human PTH (1-84), human PTH (1-34), and other partial sequences, native or with substitutions;

(k) vitamin D or vitamin D derivative is selected from natural vitamin D, 25-OH-vitamin D3, 1α,25(OH)$_2$ vitamin D3, 1α-OH-vitamin D3, 1α-OH-vitamin D2, dihydrotachysterol, 26,27-F6-1α,25(OH)$_2$ vitamin D3, 19-nor-1α,25(OH)$_2$ vitamin D3, 22-oxacalcitriol, calcipotriol, 1α,25(OH)$_2$-16-ene-23-yne-vitamin D3 (Ro 23-7553), EB1089, 20-epi-1α,25(OH)$_2$ vitamin D3, KH1060, ED71, 1α,24(S)-(OH)$_2$ vitamin D3, and 1α,24(R)-(OH)$_2$ vitamin D3;

(l) the dietary calcium supplement is selected from calcium carbonate, calcium citrate, and natural calcium salts; and

(m) the fluoride salts are selected from sodium fluoride and monosodium fluorophosphate (MFP);

and pharmaceutically acceptable salts thereof.

28. (Original) The method of Claim 20 which further comprises the administration of alendronate monosodium trihydrate.

29. A composition comprising a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, and a bone-strengthening agent selected from the group consisting of:

(a) an estrogen or an estrogen derivative, alone or in combination with a progestin or progestin derivative,

(b) a bisphosphonate,

(c) an antiestrogen or a selective estrogen receptor modulator,

(d) an $\alpha v\beta 3$ integrin receptor antagonist,

(e) a cathepsin K inhibitor,

(f) an HMG-CoA reductase inhibitor,

(g) an osteoclast vacuolar ATPase inhibitor,

(h) an antagonist of VEGF binding to osteoclast receptors,

(i) an activator of peroxisome proliferator-activated receptor γ,

(j) calcitonin,

(k) a calcium receptor antagonist,

(l) parathyroid hormone or analog thereof,

(m) a growth hormone secretagogue,

(n) human growth hormone,

(o) insulin-like growth factor,

(p) a P-38 protein kinase inhibitor,

(q) bone morphogenetic protein,

(r) an inhibitor of BMP antagonism,

(s) a prostaglandin derivative,

(t) vitamin D or vitamin D derivative,

(u) vitamin K or vitamin K derivative,

(v) ipriflavone,

(w) fluoride salts,
(x) dietary calcium supplement, and
(y) osteoprotegerin.

30. (Original) The use of a compound of structural formula I for the preparation of a medicament useful for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation.

31. (Original) The use of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament useful for activating the function of the androgen receptor in a patient in need thereof.

32. (Presently amended) The use of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament useful for ~~treating a condition in a patient in need of such~~ the treatment of ~~which is caused by androgen deficiency or which can be ameliorated by androgen administration selected from the group consisting of~~ osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia~~, and~~ or frailty~~, aging skin, male hypogonadism, female sexual dysfunction, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, arthritis and joint repair~~.

33. (Original) The method of Claim 16 wherein the bone-strengthening agent is selected from the group consisting of:

(a) an estrogen or an estrogen derivative, alone or in combination with a progestin or progestin derivative,
(b) a bisphosphonate,
(c) an antiestrogen or a selective estrogen receptor modulator,
(d) an $\alpha v\beta 3$ integrin receptor antagonist,
(e) a cathepsin K inhibitor,
(f) an osteoclast vacuolar ATPase inhibitor,
(g) calcitonin, and
(h) osteoprotegerin.

34. (Original) The method of Claim 20 wherein the bone-strengthening agent is selected from the group consisting of:

(a) an estrogen or an estrogen derivative, alone or in combination with progestin or progestin derivative,
(b) a bisphosphonate,
(c) an antiestrogen or a selective estrogen receptor modulator,
(d) an αvβ3 integrin receptor antagonist,
(e) a cathepsin K inhibitor,
(f) an osteoclast vacuolar ATPase inhibitor,
(g) calcitonin, and
(i) osteoprotegerin.

35. (Original) A compound of structural formula II:



(II)

wherein

"a" represents a single bond or a double bond;

R^1 is hydrogen, hydroxymethyl, or C_{1-3} alkyl, wherein alkyl is unsubstituted or substituted with one to seven fluorine atoms;

R^2 is hydrogen, fluorine, or C_{1-4} alkyl when "a" represents a double bond; or two R^2 substituents are each independently hydrogen, fluorine, or C_{1-4} alkyl when "a" represents a single bond;

R^4 is hydrogen, C_{1-4} alkyl, C_{2-4} alkenyl, or C_{2-4} alkynyl;

one of R^5 and R^6 is hydrogen or methyl and the other is selected from the group consisting of

(a) hydrogen,
(b) C_{1-8} alkyl,
(c) C_{2-8} alkenyl,

wherein alkyl and alkenyl are unsubstituted or substituted one to three groups independently selected from amino, cyano, halogen, hydroxy, oxo, carboxy, C_{1-4} alkoxy, C_{1-4} alkoxyC_{1-4} alkoxy, and C_{1-3} alkyloxycarbonyl;

(d) fluoro,
(e) cyano,
(f) hydroxy,
(g) C_{1-6} alkoxy,
(h) C_{1-6} alkylcarbonyloxy,
(i) C_{1-6} alkylthio,
(j) C_{1-6} alkylsulfonyl,
(k) C_{3-8} cycloalkyl C_{0-6} alkyl,
(l) C_{3-8} cycloheteroalkyl C_{0-6} alkyl,
(m) aryl C_{0-6} alkyl,
(n) aryl C_{2-4} alkenyl,
(o) amino,
(p) C_{1-3} acylamino,
(q) aryl C_{1-3} acylamino,
(r) C_{1-6} alkylamino,
(s) di(C_{1-6} alkyl)amino,
(t) aryl-C_{0-3} alkylamino,
(u) di(aryl-C_{0-3} alkyl)amino,
(v) C_{3-6} cycloalkyl C_{0-2} alkylamino,
(w) C_{1-8} alkylsulfonylamino,
(x) aryl C_{0-3} alkylsulfonylamino,
(y) C_{1-8} alkyloxycarbonylamino,
(z) aryl C_{0-3} alkyloxycarbonylamino,
(aa) aminocarbonylamino,
(bb) C_{1-8} alkylaminocarbonylamino,
(cc) aryl C_{0-3} alkylaminocarbonylamino,
(dd) C_{1-8} alkylaminocarbonyloxy, and
(ee) aryl C_{0-3} alkylaminocarbonyloxy;

or R^5 and R^6 taken together with the carbon atom to which they are attached can form a C_{3-6} spirocyclic ring system optionally containing a heteroatom selected from O, S, and NC_{0-4} alkyl;

or R^5 and R^6 taken together can be $=CR^9R^{10}$, wherein R^9 and R^{10} are each independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl C_{0-3} alkyl, C_{3-6} cycloheteroalkyl C_{0-3} alkyl, and aryl C_{0-3} alkyl; or R^9 and R^{10} taken together with the carbon atom to which they are attached can form a 3- to 6-membered ring optionally containing a heteroatom selected from O, S, NH,
NC_{1-4} alkyl, and NC_{1-4} alkyloxycarbonyl;

wherein the aryl group in all instances above is selected from the group consisting of

(1) phenyl,
(2) naphthyl,
(3) benzimidazolyl,
(4) benzofuranyl,
(5) benzothiophenyl,
(6) benzoxazolyl,
(7) benzothiazolyl,
(16) benzodihydrofuranyl,
(17) 1,3-benzodioxolyl,
(10) indolyl,
(11) quinolyl,
(12) isoquinolyl,
(13) furanyl,
(14) thienyl,
(15) imidazolyl,
(16) oxazolyl,
(17) thiazolyl,
(18) isoxazolyl,
(19) isothiazolyl,
(20) pyrazolyl,
(21) pyrrolyl,
(22) pyridyl,
(23) pyrimidyl,
(24) pyrazinyl,
(25) thiadiazolyl,
(26) oxadiazolyl,
(27) triazolyl, and
(28) tetrazolyl;

wherein the aryl group as defined in items (1) to (28) is unsubstituted or substituted with one to three groups independently selected from halogen, aryl, C_{1-8} alkyl, C_{3-8} cycloalkyl, C_{3-8} cycloheteroalkyl, aryl C_{1-6}alkyl, amino C_{0-6}alkyl, C_{1-6} alkylamino C_{0-6}alkyl, (C_{1-6} alkyl)$_2$amino C_{0-6}alkyl, aryl C_{0-6} alkylamino C_{0-6}alkyl, (aryl C_{0-6} alkyl)$_2$amino C_{0-6}alkyl, C_{1-6} alkylthio, aryl C_{0-6}alkylthio, C_{1-6} alkylsulfinyl, aryl C_{0-6}alkylsulfinyl, C_{1-6} alkylsulfonyl, aryl C_{0-6}alkylsulfonyl, C_{1-6} alkoxy C_{0-6}alkyl, aryl C_{0-6} alkoxy C_{0-6}alkyl, hydroxycarbonyl C_{0-6}alkyl, C_{1-6} alkoxycarbonyl C_{0-6}alkyl, aryl C_{0-6} alkoxycarbonyl C_{0-6}alkyl, hydroxycarbonyl C_{1-6} alkyloxy, hydroxy C_{0-6}alkyl, cyano, nitro, perfluoroC_{1-4}alkyl, perfluoroC_{1-4}alkoxy, oxo, C_{1-6} alkylcarbonyloxy, aryl C_{0-6}alkylcarbonyloxy, C_{1-6} alkylcarbonylamino, aryl C_{0-6} alkylcarbonylamino, C_{1-6} alkylsulfonylamino, aryl C_{0-6}alkylsulfonylamino, C_{1-6} alkoxycarbonylamino, aryl C_{0-6} alkoxycarbonylamino, C_{1-6}alkylamino-carbonylamino, aryl C_{0-6}alkylaminocarbonylamino, (C_{1-6}alkyl)$_2$ aminocarbonylamino, (aryl C_{0-6}alkyl)$_2$ aminocarbonylamino, (C_{1-6}alkyl)$_2$ aminocarbonyloxy, and (aryl C_{0-6}alkyl)$_2$ aminocarbonyloxy; with the provisos that (a) when "a" is a single or double bond, R^1 is hydrogen or methyl, and R^2, R^5 and R^6 are hydrogen, then R^4 is not hydrogen, methyl, allyl, or n-propyl; and (b) when "a" is a single bond, R^1 is methyl, and R^4 and R^6 are hydrogen, then R^5 is not methyl, ethyl, isopropyl, or allyl.

36. (Original) The compound of Claim 35 wherein R^1 is hydrogen or methyl and R4 is hydrogen.

37. (Original) The compound of Claim 35 wherein one of R^5 and R^6 is hydrogen or methyl and the other is selected from the group consisting of

(a) hydrogen,

(b) fluorine,

(c) C_{1-3} alkyl, wherein alkyl is unsubstituted or substituted one to three groups independently selected from amino, cyano, halogen, hydroxy, oxo, carboxy, C_{1-4} alkoxy, C_{1-3} alkoxy-C_{1-3} alkoxy, and C_{1-3} alkyloxycarbonyl; and

(d) arylmethyl, wherein aryl is selected from the group consisting of phenyl, naphthyl, pyridyl, furanyl, pyrrolyl, thiazolyl, imidazolyl, benzofuranyl, and 1,3-benzodioxolyl, wherein the aryl group is unsubstituted or substituted with one to two groups independently selected from halogen, C_{1-4} alkyl, C_{1-4} alkoxy, cyano, trifluoromethyl, and trifluoromethoxy;

or R^5 and R^6 taken together with the carbon atom to which they are attached

can form a C_{3-6} spirocyclic ring system optionally containing a heteroatom selected from O, S, NH, NC_{1-4} alkyl, and N_{1-4} alkyloxycarbonyl;
or R^5 and R^6 taken together can be $=CR^9R^{10}$, wherein R^9 and R^{10} are each independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl-C_{0-3} alkyl, C_{3-6} cycloheteroalkyl-C_{0-3} alkyl, aryl C_{0-1} alkyl; or R^9 and R^{10} taken together with the carbon atom to which they are attached can form a 3- to 6-membered ring optionally containing a heteroatom selected from O, S, NH,
NC_{1-4} alkyl, and NC_{1-4} alkyloxycarbonyl.

38. (Original) The compound of Claim 37 wherein one of R^5 and R^6 is hydrogen and the other is arylmethyl wherein aryl is as defined in Claim 37.

39. (Original) The compound of Claim 38 wherein R^5 is hydrogen and R^6 is arylmethyl.

40. (Original) The compound of Claim 39 wherein R^1 is hydrogen or methyl and R^4 is hydrogen.

41. (Original) The compound of Claim 40 wherein "a" represents a double bond.

42. (Original) The compound of Claim 37 wherein R^5 and R^6 taken together are =CHaryl wherein aryl is as defined in Claim 37.

43. (Original) The compound of Claim 42 wherein R^1 is hydrogen or methyl and R^4 is hydrogen.

44. (Original) The compound of Claim 43 wherein "a" represents a double bond.

45. (Original) The compound of Claim 35 selected from the group consisting of:
16α-fluoro-17β-hydroxy-4-methyl-4-aza-5α-androst-1-en-3-one;
16β-fluoro-17α-hydroxy-4-methyl-4-aza-5α-androst-1-en-3-one;
16α-fluoro-17β-hydroxy-4,17α-dimethyl-4-aza-5α-androst-1-en-3-one;

16β-fluoro-17β-hydroxy-4-methyl-4-aza-5α-androst-1-en-3-one;
2α-fluoro-17β-hydroxy-4-methyl-4-aza-5α-androstan-3-one;
2β-fluoro-17β-hydroxy-4-methyl-4-aza-5α-androstan-3-one;
2,2-difluoro-17β-hydroxy-4-methyl-4-aza-5α-androstan-3-one;
17β-hydroxy-2α,4-dimethyl-4-aza-5α-androstan-3-one;
17β-hydroxy-16α-(methoxymethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(ethoxymethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(2-methoxyethyloxymethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(ethyloxycarbonylmethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(carboxymethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(2-hydroxyethyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-allyl-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-4,16α,17α-trimethyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-17α-ethyl-4-methyl-4-aza-5α-androstan-3-one;
17β-hydroxy-16α-(2-trifluoromethylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(3-trifluoromethylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(4-trifluoromethylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(2-fluorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(3-fluorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(4-fluorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(3-chlorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(4-chlorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(4-trifluoromethoxybenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(3-methoxybenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-benzyl-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(2-methylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16α-(2-naphthyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16β-(2-methylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16β-(3-methylbenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16β-(4-chlorobenzyl)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-chlorobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-fluorobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-trifluoromethylbenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-trifluoromethylbenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-methoxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;

17β-hydroxy-16-(3,4-methylenedioxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(5-methoxy-3,4-methylenedioxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3,5-difluorobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3,5-dichlorobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3,4-dimethoxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(pyridin-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(pyridin-4-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(cyclopropylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(furan-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(1-methyl-imidazol-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-cyclohexylidene-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-ethylidene-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-isopropylidene-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-isobutylidene-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(piperidin-4-ylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(N-t-butyloxycarbonylpiperidin-4-ylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(1,3-thiazol-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(benzofuran-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(5-hydroxymethyl-furan-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(1-methyl-pyrrol-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(pyrrol-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-ethoxy-pyrimidin-5-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(pyrimidin-5-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-methyl-pyrimidin-5-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-trifluoromethoxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(4-trifluoromethoxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(4-dimethylaminobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(9-methoxy-quinolin-2-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;

17β-hydroxy-16-(quinoxalin-6-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(quinoxalin-7-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-hydroxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-hydroxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(4-hydroxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(pyridin-3-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(N-methylpiperidin-4-ylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-chloro-4-dimethylaminobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(2-amino-pyridin-3-ylmethylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-carboxymethyl-benzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-carboxybenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(3-nitrobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
17β-hydroxy-16-(4-nitrobenzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one; and
17β-hydroxy-16-(benzylidene)-4-methyl-4-aza-5α-androst-1-en-3-one;
or a pharmaceutically acceptable salt thereof.

46. (Original) A composition comprising a compound of Claim 35 and a pharmaceutically acceptable carrier.